In Vivo Chimeric Antigen Receptor T-Cell Technology

Mechanism

Related News

Eli Lilly Reports Strong 2025 Clinical Trial Results, Acquires Orna Therapeutics

Feb 14, 2026

Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.

Eli Lilly Expands Pipeline with $2.4B Orna Acquisition and AI Drug Development Push

Feb 14, 2026

Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.